Adaptimmune to participate in the guggenheim securities smid cap biotech conference february 6, 2025

Philadelphia, pennsylvania and oxford, united kingdom--(newsfile corp. - january 30, 2025) - adaptimmune therapeutics plc (nasdaq: adap), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the guggenheim securities smid cap biotech conference this february. guggenheim securities smid cap biotech conference, new york, ny fireside chat with adrian rawcliffe, ceo: february 6 at 3:00 p.m.
SMID Ratings Summary
SMID Quant Ranking